August 4, 2015 – Press Release – New York, NY – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented DelMar Pharmaceuticals, Inc. (OTCQX: DMPI), a biopharmaceutical company focused on developing and commercializing cancer therapies, in a registered direct offering. DelMar accepted subscriptions from institutional and accredited investors and approximately 4.0 million common stock and warrants for an aggregate price of $2.5 million. Each common share had a purchase price of $0.60 per share. The warrants had an exercise price of $0.75 per share.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Gregory Sichenzia, David Manno and Associate Jeffrey Cahlon.
- Sichenzia Ross Ference Carmel LLP Represents R.F. Lafferty in $5.5 Million Initial Public Offering of Empro Group - July 2, 2025
- Partner Ross Carmel Featured on NASDAQ TradeTalks with Jill Malandrino Discussing the State of the IPO Market - July 2, 2025
- Sichenzia Ross Ference Carmel LLP Represents Dominari Securities in $6.5 Million Registered Direct Offering of Thumzup Media Corporation - July 1, 2025